Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial

被引：4
|
作者：
Pignata, S.
Scambia, G.
Savarese, A.
Sorio, R.
Breda, E.
Legge, F.
Gebbia, V.
Musso, P.
Gallo, C.
Perrone, F.
机构：
[1] MITO, Rome, Italy
[2] Ist Regina Elena, I-00161 Rome, Italy
[3] CRO, Aviano, Italy
[4] Osped Fatebenefratelli, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] La Maddalena Clin, Palermo, Italy
[7] Osped M Ascoli ARNAS, Palermo, Italy
[8] Univ Naples 2, Naples, Italy
[9] Natl Canc Inst, Clin Trials Unit, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 18期
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba5033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5033
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial
    Shen, Yuanming
    Kong, Beihua
    Xia, Bairong
    Wang, Fei
    Yin, Rutie
    Li, Qingshui
    Yue, Ying
    Kang, Shan
    He, Liping
    Wang, Ke
    Meng, Yuanguang
    Wang, Shixuan
    Qu, Pengpeng
    Huang, Xianghua
    Guo, Ruixia
    Yan, Ping
    Pan, Mei
    Lou, Ge
    Cheng, Wenjun
    Xie, Xing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Gladieff, L.
    Ferrero, A.
    De Rauglaudre, G.
    Brown, C.
    Vasey, P.
    Reinthaller, A.
    Pujade-Lauraine, E.
    Reed, N.
    Lorusso, D.
    Siena, S.
    Helland, H.
    Elit, L.
    Mahner, S.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1185 - 1189
  • [23] An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer
    Dalton, Heather J.
    Yu, Xinhua
    Hu, Lilian
    Kapp, Daniel S.
    Benjamin, Ivor
    Monk, Bradley J.
    Chan, John K.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (02) : 199 - 204
  • [24] Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study
    Power, Patti
    Stuart, Gavin
    Oza, Amit
    Provencher, D.
    Bentley, James R.
    Miller, Wilson H., Jr.
    Pouliot, Jean-Francois
    GYNECOLOGIC ONCOLOGY, 2009, 114 (03) : 410 - 414
  • [25] Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    U Wagner
    C Marth
    R Largillier
    J Kaern
    C Brown
    M Heywood
    T Bonaventura
    I Vergote
    M C Piccirillo
    R Fossati
    V Gebski
    E P Lauraine
    British Journal of Cancer, 2012, 107 : 588 - 591
  • [26] Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    Wagner, U.
    Marth, C.
    Largillier, R.
    Kaern, J.
    Brown, C.
    Heywood, M.
    Bonaventura, T.
    Vergote, I.
    Piccirillo, M. C.
    Fossati, R.
    Gebski, V.
    Lauraine, E. P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 588 - 591
  • [27] A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients
    Vasey, P.
    Largillier, R.
    Gropp, M.
    Gebski, V.
    Sandvei, R.
    Elit, L.
    Angleitner-Boubezinek, L.
    Reed, N.
    Pignata, S.
    Ferrero, A. M.
    EJC SUPPLEMENTS, 2009, 7 (03): : 11 - 11
  • [28] The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
    Pignata, Sandro
    Scambia, Giovanni
    Lorusso, Domenica
    De Giorgi, Ugo
    Nicoletto, Maria Ornella
    Lauria, Rossella
    Mosconi, Anna Maria
    Sacco, Cosimo
    Omarini, Claudia
    Tagliaferri, Pierosandro
    Ferrandina, Gabriella
    Cinieri, Saverio
    Savarese, Antonella
    Valabrega, Giorgio
    Pisano, Carmela
    Salutari, Vanda
    Raspagliesi, Francesco
    Kopf, Barbara
    Cecere, Sabrina Chiara
    Amadio, Giulia
    Maltese, Giuseppa
    Di Napoli, Marilena
    Greggi, Stefano
    Signoriello, Simona
    Daniele, Gennaro
    Sacco, Alessandra
    Losito, Simona
    Normanno, Nicola
    Perrone, Francesco
    Gallo, Ciro
    Piccirillo, Maria Carmela
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 535 - 540
  • [29] Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
    Sehouli, J.
    Chekerov, R.
    Reinthaller, A.
    Richter, R.
    Gonzalez-Martin, A.
    Harter, P.
    Woopen, H.
    Petru, E.
    Hanker, L. C.
    Keil, E.
    Wimberger, P.
    Klare, P.
    Kurzeder, C.
    Hilpert, F.
    Belau, A. K.
    Zeimet, A.
    Bover-Barcelo, I.
    Canzler, U.
    Mahner, S.
    Meier, W.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2236 - 2241
  • [30] A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).
    Naumann, R. Wendel
    Gilbert, Lucy
    Miller, Anthonette M.
    Ma, Hong
    Ghamande, Sharad A.
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345